PTC
ADPT icon

Private Trust Company’s Adaptive Biotechnologies ADPT Stock Holding History

Private Trust Company’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-880
Closed -$13.2K – 2541
2025
Q3 		$13.2K Buy
880
+91
+12% +$1.11K ﹤0.01% 1802
2025
Q2 		$9.19K Buy
+789
New +$7.17K ﹤0.01% 1855

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Private Trust Company's ADPT Position: Q4 2025 in Review

Private Trust Company sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 880 shares — an estimated $13.2K sold.

Private Trust Company first reported a position in ADPT in Q2 2025 and held it in 2 quarters. The position peaked at $13.2K in Q3 2025. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • Private Trust Company reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Private Trust Company sold 880 Adaptive Biotechnologies shares in Q4 2025, an estimated $13.2K.
  • Private Trust Company first reported a position in Adaptive Biotechnologies in Q2 2025 and held it in 2 quarters.
  • Private Trust Company's Adaptive Biotechnologies position peaked at $13.2K in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Private Trust Company's 13F filing for Q4 2025, filed 26 Jan 2026.